[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H14O3
Molecular Weight 242.2699
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EQUOL

SMILES

OC1=CC=C(C=C1)[C@H]2COC3=C(C2)C=CC(O)=C3

InChI

InChIKey=ADFCQWZHKCXPAJ-GFCCVEGCSA-N
InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H14O3
Molecular Weight 242.2699
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15883431

EQUOL, (-)- is the (S)-enantiomer of the naturally-occurring isoflavandiol estrogen, equol. EQUOL, (-)- (US-131), is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). S-equol is the exclusive product of human intestinal bacterial synthesis from soy isoflavones. Two-Phase 1 studies have seen completed and published; AUS-131 was safe and well-tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has recently been completed (169 patients). A second Phase 2a trial in men with benign prostatic hyperplasia (BPH) is on track.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.73 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4953 nM
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1907 nM
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
25299 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
8584 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.2 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
7.4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EQUOL, (-)- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The production of S-equol from daidzein is associated with a cluster of three genes in Eggerthella sp. YY7918.
2016
Phytoestrogen Metabolism by Adult Human Gut Microbiota.
2016 Aug 9
Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer.
2016 Jul 5
Patents

Sample Use Guides

The following doses have been studied in scientific research: BY MOUTH: For menopausal symptoms such as hot flashes: 10-40 mg per day in divided doses. For preventing weak bones (osteoporosis): 10 mg per day. For reducing skin wrinkles: 5 or 15 mg two times per day. For metabolic syndrome: 10 mg per day.
Route of Administration: Oral
S-equol (EQUOL, (-)-) inhibited the growth of the breast cancer cell line MDA-MB-231 (> or = 10 uM) and the prostate cancer cell lines LNCaP (> or = 5 uM) and LAPC-4 (> or = 2.5 uM).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:44:50 GMT 2025
Edited
by admin
on Mon Mar 31 18:44:50 GMT 2025
Record UNII
2T6D2HPX7Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EQUOL
INCI   MI  
INCI  
Official Name English
EQUOL (S)-FORM
Preferred Name English
EQUOL [MI]
Common Name English
2H-1-BENZOPYRAN-7-OL, 3,4-DIHYDRO-3-(4-HYDROXYPHENYL)-, (3S)-
Systematic Name English
(3S)-3,4-DIHYDRO-3-(4-HYDROXYPHENYL)-2H-1-BENZOPYRAN-7-OL
Systematic Name English
S-EQUOL
Common Name English
EQUOL, (S)-
Common Name English
EQUOL, (-)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2182
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID0022309
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
FDA UNII
2T6D2HPX7Q
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
DAILYMED
2T6D2HPX7Q
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
SMS_ID
300000025997
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
CAS
531-95-3
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
RXCUI
1803717
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
MERCK INDEX
m4971
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL198877
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
DRUG BANK
DB11674
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
NCI_THESAURUS
C120313
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
WIKIPEDIA
Equol
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
PUBCHEM
91469
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-522-2
Created by admin on Mon Mar 31 18:44:50 GMT 2025 , Edited by admin on Mon Mar 31 18:44:50 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDING
Ki
TARGET -> AGONIST
EC50
TARGET -> AGONIST
Ki
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Produced by intestinal microbiota. Similar activity as estrodiol
Related Record Type Details
ACTIVE MOIETY